These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28940404)

  • 1. A rapid and simple HPTLC assay for therapeutic drug monitoring of capecitabine in colorectal cancer patients.
    Thorat SG; Chikhale RV; Tajne MR
    Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28940404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of HPLC and HPTLC Methods for Therapeutic Drug Monitoring of Capecitabine in Colorectal Cancer Patients.
    Thorat SG; Chikhale RV; Tajne MR
    J Chromatogr Sci; 2020 Jan; 57(10):892-900. PubMed ID: 31609432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
    Schreiber V; Kitzmueller M; Poxhofer M; Gintersdorfer S; Neudorfer C; Lichtneckert M; Dittrich C; Czejka M
    Anticancer Res; 2014 Jul; 34(7):3371-6. PubMed ID: 24982342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E; Schulman KL; McKenna EF; Cartwright T
    Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.
    Rachar V; Czejka M; Kitzmueller M; Buchner P; Lichtneckert M; Greil R; Geiler H; Dittrich C
    Anticancer Res; 2016 Sep; 36(9):4715-23. PubMed ID: 27630318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
    Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates.
    Ito H; Yamaguchi H; Fujikawa A; Tanaka N; Furugen A; Miyamori K; Takahashi N; Ogura J; Kobayashi M; Yamada T; Mano N; Iseki K
    J Pharm Biomed Anal; 2012 Dec; 71():99-103. PubMed ID: 22954448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
    Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
    Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Carrato A; Gallego-Plazas J; Guillén-Ponce C
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
    Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast and sensitive liquid chromatography/electrospray mass spectrometry method to study ocular penetration of EDL-155, a novel antitumor agent for retinoblastoma in rats.
    Ramagiri S; Ma F; Kosanam H; Wang X; Patil R; Miller DD; Geisert E; Yates CR
    J Mass Spectrom; 2009 May; 44(5):786-93. PubMed ID: 19160451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
    Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-validation of a mass spectrometric-based method for the therapeutic drug monitoring of irinotecan: implementation of matrix-assisted laser desorption/ionization mass spectrometry in pharmacokinetic measurements.
    Calandra E; Posocco B; Crotti S; Marangon E; Giodini L; Nitti D; Toffoli G; Traldi P; Agostini M
    Anal Bioanal Chem; 2016 Jul; 408(19):5369-77. PubMed ID: 27235158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
    Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
    BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
    Ding J; Chen X; Dai X; Zhong D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():108-15. PubMed ID: 22503745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
    Cao Y; Liao C; Tan A; Liu L; Mo Z; Gao F
    Colorectal Dis; 2010 Jan; 12(1):16-23. PubMed ID: 19220378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.